Novo Nordisk launches a 'Novo Way' corporate transformation to improve patient-focused commercialization and defend its market share against aggressive competition from Eli Lilly's obesity drug portfolio.
Eli Lilly's Zepbound and Foundayo have captured significant share in injectable and oral obesity treatments, directly challenging Novo's leadership and benefiting from aggressive commercialization.
Novo Nordisk acknowledges losing competitive ground to Eli Lilly in obesity drugs and is undertaking a cultural reset to improve commercialization, indicating strategic pressure but not an immediate financial failure.
Novo Nordisk is rebranding as 'Novo' as part of a strategic cultural overhaul led by CEO Mike Doustdar. The initiative aims to sharpen commercial execution and regain competitive momentum in the $100 billion U.S. obesity drug market, where Eli Lilly's Zepbound and Foundayo have successfully challenged Novo's early leadership.
The rebrand is a symbolic and structural component of a broader cultural reset aimed at making the company more competitive, customer-focused, and responsive to market shifts in the obesity drug sector.
Eli Lilly has successfully challenged Novo's dominance in both the injectable and oral obesity drug markets, with its Foundayo treatment capturing over 30% of new U.S. oral-treatment patients.